The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy.
B. P. Schneider
No relevant relationships to disclose
M. Wang
No relevant relationships to disclose
V. Stearns
Honoraria - AstraZeneca
Research Funding - Abraxis BioScience; Merck; Novartis; Pfizer
S. Martino
No relevant relationships to disclose
V. E. Jones
No relevant relationships to disclose
E. A. Perez
Research Funding - Genentech; Sanofi
T. J. Saphner
No relevant relationships to disclose
A. C. Wolff
No relevant relationships to disclose
G. W. Sledge
No relevant relationships to disclose
W. Wood
No relevant relationships to disclose
N. E. Davidson
No relevant relationships to disclose
J. A. Sparano
No relevant relationships to disclose